<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>22749511</identifier>
<setSpec>0210-5705</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Molina Pérez, Esther</dc:author>
<dc:author>Castroagudín, Javier F</dc:author>
<dc:author>Alvarez Castro, Ana M</dc:author>
<dc:author>Varo Pérez, Evaristo</dc:author>
<dc:author>Seijo Ríos, Susana</dc:author>
<dc:description xml:lang="en">We present the case of a liver transplant recipient with alcoholic liver cirrhosis and early-stage hepatocellular carcinoma who developed biopsy-proven acute steroid-resistant rejection 3 months after liver transplantation. After the failure of immunosuppressive therapy with intravenous boluses of 6-methyl-prednisolone and switching of the immunosuppressive regimen to tacrolimus plus mycophenolate mofetil, two doses of intravenous basiliximab were administered four days apart. Clinical, analytical, and biopsy-proven histological response was complete. No basiliximab-related adverse events were detected. Basiliximab may represent an alternative in liver transplantation immunosuppression to treat acute steroid-resistant rejection, without increasing the incidence of infections, neoplasms, or other adverse events, as shown by this case.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>2012 Nov </dc:date>
<dc:title xml:lang="es">Basiliximab en el tratamiento del rechazo celular agudo resistente a los corticoides postrasplante hepático.</dc:title>
<dc:title xml:lang="en">[Basiliximab in the treatment of acute steroid-resistant rejection after liver transplantation].</dc:title>
<dc:publisher>Gastroenterologia y hepatologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
